REZOLUTE, INC.

RZLT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-74.4M $-68.5M $-51.8M $-41.1M $-20.9M $-20.3M $-30.4M $-29.9M
Depreciation & Amortization $31.0K $36.0K $30.0K $13.0K $13.0K $18.0K $49.0K $1.1M
Depreciation $31.0K $36.0K $30.0K $13.0K $13.0K $11.0K $41.0K $1.1M
Amortization $7.0K $7.0K $7.0K
Stock-Based Compensation $7.1M $7.4M $7.3M $3.7M $4.0M $3.3M $2.6M $5.1M
Net Cash from Operating Activities $-69.1M $-57.4M $-44.5M $-39.6M $-20.4M $-24.2M $-15.3M $-14.1M
Investing Activities
Capital Expenditures $153.0K $0 $47.0K $6.0K
Business Acquisitions
Net Cash from Investing Activities $-14.5M $48.7M $-101.5M $0 $0 $231.0K $1.7M
Financing Activities
Dividends Paid
Stock Repurchases $3.0K
Net Cash from Financing Activities $107.3M $63.0M $11.6M $149.0M $51.5M $22.6M $25.0M $9.5M
Net Change in Cash $23.7M $54.4M $-134.4M $109.4M $31.1M $-1.6M $9.9M
Free Cash Flow $-44.6M $-24.2M $-15.4M $-14.1M
← Newer Page 1 of 2 Older →